Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoricoxib.

Deborah J Cochrane1, Blair Jarvis, Gillian M Keating

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|December 6, 2002
PubMed
Summary
This summary is machine-generated.

Etoricoxib, a selective cyclo-oxygenase (COX)-2 inhibitor, effectively manages pain and inflammation in various conditions like arthritis and postoperative pain. It demonstrates comparable or superior efficacy to other analgesics with a significantly lower risk of gastrointestinal complications compared to non-selective NSAIDs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Pain Management

Background:

  • Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor NSAID.
  • It exhibits a higher COX-1 to COX-2 selectivity ratio compared to other COX-2 inhibitors.
  • Non-selective NSAIDs are associated with significant gastrointestinal risks.

Purpose of the Study:

  • To evaluate the efficacy and safety of etoricoxib in various pain and inflammatory conditions.
  • To compare etoricoxib's effectiveness against placebo and other analgesics.
  • To assess etoricoxib's gastrointestinal safety profile relative to non-selective NSAIDs.

Main Methods:

  • Clinical trials involving patients with rheumatoid arthritis, osteoarthritis, postoperative dental pain, chronic low back pain, acute gout, and primary dysmenorrhoea.

Related Experiment Videos

  • Etoricoxib was compared to placebo, naproxen, diclofenac, indomethacin, naproxen sodium, ibuprofen, and paracetamol/codeine.
  • Gastrointestinal adverse events (perforations, ulcers, bleeds) and treatment discontinuations due to GI symptoms were recorded.

    • Main Results:

    • Etoricoxib demonstrated significant improvements in disease activity and pain scores in rheumatoid arthritis and osteoarthritis patients compared to placebo.
    • Etoricoxib showed comparable or superior efficacy to naproxen, diclofenac, indomethacin, and naproxen sodium in various pain conditions.
    • Significantly fewer upper gastrointestinal (GI) perforations, ulcers, or bleeds were observed with etoricoxib compared to non-selective NSAIDs.
    • Treatment discontinuation due to GI symptoms was significantly lower with etoricoxib.

    Conclusions:

    • Etoricoxib is an effective treatment for rheumatoid arthritis, osteoarthritis, and various acute and chronic pain conditions.
    • It offers a favorable efficacy profile comparable to existing analgesics.
    • Etoricoxib presents a significantly improved gastrointestinal safety profile compared to non-selective NSAIDs, reducing the risk of serious GI events.